Client Success

Congratulations to our leasing client, City Therapeutics, on its launch to lead the future of RNA interference (RNAi)-based medicine

Congratulations to our client on its launch. City Therapeutics is focused on the development of new medicines that use RNAi. The Sherin and Lodgen team, led by John J. Slater III, represented City Therapeutics on the leasing of their new space in Cambridge, MA.

City Therapeutics is harnessing next generation engineering of small interfering RNAs (siRNAs) to improve and expand the reach of RNAi-based medicines. The company is building a pipeline of innovative RNAi therapeutics to make a significant impact for patients across multiple therapeutic areas. Co-founded by pioneering executives and scientists in RNAi, City Therapeutics is based in Cambridge, MA, and has raised $135 million from leading life sciences investors.